Emergent Biosolutions
EBS
191 hedge funds and large institutions have $465M invested in Emergent Biosolutions in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 54 increasing their positions, 72 reducing their positions, and 34 closing their positions.
47% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $1.27M
4% less funds holding
Funds holding: 198 → 191 (-7)
4.33% less ownership
Funds ownership: 92.64% → 88.31% (-4.3%)
11% less capital invested
Capital invested by funds: $524M → $465M (-$58.6M)
12% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 34
25% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$6.56M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.16M |
| 3 |
Millennium Management
New York
|
+$4.91M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.68M |
| 5 |
BlackRock
New York
|
+$3.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$15.3M |
| 2 |
Man Group
London,
United Kingdom
|
-$10.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.99M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$4.3M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$4.19M |
EBS Hedge Fund Activity: Q1 2023 in Review
191 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2023, worth a combined $465M — down 11% from $524M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of EBS and 30 opened new positions — a net loss of 4 holders — while 72 trimmed existing stakes and 54 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $6.56M. The largest seller was Invesco, cutting an estimated $15.3M.
- 191 institutional investors held Emergent Biosolutions (EBS) as of Q1 2023, down from 198 in Q4 2022.
- Funds reported $465M of Emergent Biosolutions stock for Q1 2023, down 11% quarter-over-quarter.
- 30 funds opened new Emergent Biosolutions positions in Q1 2023 and 34 closed out, a net change of -4 holders.
- The largest Emergent Biosolutions buyer in Q1 2023 was Bridgeway Capital Management, an estimated $6.56M added.
- The largest Emergent Biosolutions seller in Q1 2023 was Invesco, an estimated $15.3M sold.
Based on aggregated 13F filings for Q1 2023.